Lu Zheng
Impact in
- Cancer Research top 2%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- Cancer, Hypoxia, and Metabolism
- Cancer, Lipids, and Metabolism
- Molecular Biology top 5%
- RNA modifications and cancer
Papers in
-
- MicroRNA in disease regulation 9
- Cancer-related molecular mechanisms research 9
- Cancer, Lipids, and Metabolism 7
- Hepatology 14
- Hepatocellular Carcinoma Treatment and Prognosis 11
- Co-authors
- Guanghua LuoXiaoying ZhangNan YouNing XuXiaobing HuangBernard L. SchneiderPeter Nilsson‐EhleGraham Knott
- Journals
- Acta Histochemica (5 papers)BMC Cancer (3 papers)Frontiers in Neurology (3 papers)Molecular Cancer (3 papers)Annals of Translational Medicine (3 papers)
- Partner nations
- ChinaSwedenUnited States
In The Last Decade
Lu Zheng
133 papers receiving 3.0k citations
Hit Papers
Peers
Comparison fields: 5 of 119
- Cancer Research 842
- Molecular Biology 1.6k
- Hepatology 183
- Immunology 449
- Oncology 557
Countries citing papers authored by Lu Zheng
This map shows the geographic impact of Lu Zheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lu Zheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lu Zheng more than expected).
Fields of papers citing papers by Lu Zheng
This network shows the impact of papers produced by Lu Zheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lu Zheng. The network helps show where Lu Zheng may publish in the future.
Co-authors
The 25 scholars most cited alongside Lu Zheng, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 0 | |
| 3 | Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy Hit paper breakdown → | 2025 | 51 |
| 4 | 2025 | 1 | |
| 5 | 2024 | 4 | |
| 6 | 2022 | 67 | |
| 7 | 2022 | 10 | |
| 8 | 2021 | 11 | |
| 9 | 2020 | 200 | |
| 10 | 2020 | 19 | |
| 11 | 2019 | 55 | |
| 12 | Apolipoprotein M could inhibit growth and metastasis of SMMC7721 cells via vitamin D receptor signaling | 2019 | 1 |
| 13 | 2019 | 5 | |
| 14 | 2018 | 101 | |
| 15 | 2018 | 1 | |
| 16 | 2017 | 81 | |
| 17 | 2016 | 17 | |
| 18 | 2016 | 15 | |
| 19 | 2014 | 14 | |
| 20 | Effect of the spleen on intestinal barrier function in rats with acute pancreatitis | 2005 | 1 |
About Lu Zheng
Lu Zheng is a scholar working on Cancer Research, Hepatology, Oncology, Molecular Biology and Immunology, having authored 140 papers that have together received 3.0k indexed citations. Recurring topics across this work include Pancreatic and Hepatic Oncology Research (14 papers), Hepatocellular Carcinoma Treatment and Prognosis (11 papers), Sphingolipid Metabolism and Signaling (10 papers), MicroRNA in disease regulation (9 papers), Cancer-related molecular mechanisms research (9 papers), Immune cells in cancer (8 papers), Cancer, Lipids, and Metabolism (7 papers) and Circular RNAs in diseases (7 papers). The work is most often cited by research in Cancer Research (842 citations), Molecular Biology (1.6k citations), Hepatology (183 citations), Immunology (449 citations) and Oncology (557 citations). Lu Zheng has collaborated with scholars based in China, Sweden and United States. Frequent co-authors include Guanghua Luo, Xiaoying Zhang, Nan You, Ning Xu, Xiaobing Huang, Bernard L. Schneider, Peter Nilsson‐Ehle, Graham Knott, Ping Liang and Jian Zheng. Their work appears in journals such as Acta Histochemica, BMC Cancer, Frontiers in Neurology, Molecular Cancer and Annals of Translational Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.